The latest from BioStock
» Moberg Pharma's CEO on the issue and launch of MOB-015
» This is how BrainCool wants to create interest in the stroke industry
» Elicera's potential in cancer therapy published in Nature Communications
» Arcede hopes to reach a larger market than current drugs
» Medfield Diagnostics CEO on MD100 Strokefinder and the IPO
Read BioStock's weekly newsletter for week 32 here.
Morning news
publishes preclinical data showing synergies between ilixadencel and immunotherapies targeting 4-1BB. Read more.
UsDsign announces that the company has recruited 200 patients to the prospective multicenter registry for spinal fusions, PROPEL. Read more.
Iconovo consolidates its long-term financial goals for 2027. Read more.
Sigrid Therapeutics informs about strengthening study results. Read more.
sectra signs a contract for its complete solution with a large American healthcare provider. Read more.
Biosergen receives full subscription guarantees for warrants from the largest shareholders and company management. Read more.
Bioretec presents expanded scientific advice. Read more.
Insider trading
Invitation to report presentation
BergenBio Gentian Diagnostics Scandion Oncology Ultimovacs
Change in share capital
News since Tuesday lunch
Medfield Diagnostics, John Hunter Hospital, New South Wales Ambulance Service and Stroke Alliance has included the first patients in an ambulance study with MD100 Strokefinder. Read more.
Xintela has received an approved product patent in the USA for cartilage cell-based products. Read more.
Cereno Scientific will present preclinical data for the drug candidates CS014 and CS585 vid ESC Congress 2023. Read more.
Saniona has decided to carry out the offset issue to Fortune North. Read more.
ProstaLund announced that a utility model application for their product CoreFlow Soft Stent has been approved in China. Read more.
Mentice announced the launch of an updated version of Ankyras. Read more.
Audience received $82,830 in advance payment from Shenzhen Hengtong Partner Company. Read more.
Pain drains has been awarded the Nordic Health App Award 2023. Read more.
Gubra about the financial outlook. Read more.
Cool Life published a correction regarding the quarterly report published on August 11. Read more.
This morning's price development
Winner: Enzymatica +10,9%, Eurocince Vaccines +7,3%, Pila Pharma +6,6%, Biovica International +6%, Redwood Pharma +5,7%
Förlorare: Miris -11,5%, Cline Scientific -9,7%, Lipidor -8,8%, Spago Nanomedical -8,1%, Arcede Pharma -7,9%
Index: OMSX30 2181 +0,13%, Healthcare +0,18%
More from BioStock
» Issuance to take Simris Group to first license agreement
» Respiratorius CEO comments on the second quarter
» Alzinova announces positive discussions with FDA
» Respiratorius CEO comments on the second quarter
» Medfield Diagnostics wants to improve stroke diagnosis